Literature DB >> 27092957

Hydrodistention of the bladder for the treatment of bladder pain syndrome/interstitial cystitis (BPS/IC).

Tanya P Hoke1, Howard Goldstein2, Emily K Saks2, Babak Vakili2.   

Abstract

AIMS: The purpose of this study is to determine whether a transvaginal trigonal block immediately preceding cystoscopy with hydrodistention yields an additional therapeutic benefit compared to cystoscopy with hydrodistention alone for the treatment of bladder pain syndrome/interstitial cystitis (BPS/IC).
METHODS: A retrospective chart review was performed at a single-center. Performance of a trigonal block prior to hydrodistention was at the discretion of the surgeon. A trigonal block consists of injecting 0.25% bupivacaine with 1.0% Xylocaine into the anterior vagina under the trigone under cystoscopic guidance. Procedures between January 1, 2008 and December 31, 2013 were included. The primary outcome compared change in pain score from the baseline to 1-month post-operative.
RESULTS: One hundred and eighty-three patients underwent hydrodistention of the bladder. Seventy-seven were excluded and of the 106 patients remaining, 48 received a trigonal block and 58 did not. Both groups had a significant improvement in pain scores (P < 0.0001). There was no difference in change in pain score from baseline between both groups (-2.9 vs. -2.6; P = 0.694). Distention time was dichotomized into 2 and >5 min based on surgeon preference. There was no difference in change in pain score from baseline between both groups (-3.0 vs. -2.2; P = 0.061).
CONCLUSIONS: Hydrodistention of the bladder decreased pain postoperatively regardless of trigonal block or time of distention. A randomized-controlled trial is necessary to determine the benefits of duration of hydrodistention or performance of a block. Neurourol. Urodynam. 36:784-786, 2017.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  cystoscopy; pelvic pain; trigonal block

Mesh:

Year:  2016        PMID: 27092957     DOI: 10.1002/nau.23024

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.696


  4 in total

1.  Flavonoid Nobiletin Attenuates Cyclophosphamide-Induced Cystitis in Mice through Mechanisms That Involve Inhibition of IL-1β Induced Connexin 43 Upregulation and Gap Junction Communication in Urothelial Cells.

Authors:  Jin Kono; Masakatsu Ueda; Atsushi Sengiku; Sylvia O Suadicani; Je Tae Woo; Takashi Kobayashi; Osamu Ogawa; Hiromitsu Negoro
Journal:  Int J Mol Sci       Date:  2022-05-01       Impact factor: 6.208

2.  Peroxisome proliferator-activated receptor gamma agonist as a novel treatment for interstitial cystitis: A rat model.

Authors:  Amandeep Mahal; Nichole Young-Lin; Amy Dobberfuhl; Jaclyn Estes; Craig Vance Comiter
Journal:  Investig Clin Urol       Date:  2018-06-15

3.  Clinical Approach to Recurrent Voiding Dysfunction, Dysuria, and Pelvic Pain Persisting for at Least 3 Months.

Authors:  Su Jin Kim; Khae Hawn Kim
Journal:  Int Neurourol J       Date:  2022-09-30       Impact factor: 3.038

Review 4.  Potential of Endocannabinoids to Control Bladder Pain.

Authors:  Dale E Bjorling; Zun-Yi Wang
Journal:  Front Syst Neurosci       Date:  2018-05-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.